Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK bets on pioneering...

    GSK bets on pioneering cancer therapy with Adaptimmune deal

    Written by Ruby Khatun Khatun Published On 2017-09-09T09:32:17+05:30  |  Updated On 18 Aug 2021 3:06 PM IST

    LONDON: GlaxoSmithKline (GSK) said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.


    T-cell therapy is part of a new approach to treating cancer that harnesses the body's own immune cells to recognize and attack malignant cells.


    GSK's new chief executive Emma Walmsley said in July she would in future allocate 80 percent of the company's R&D budget to respiratory, HIV/infectious disease, immuno-inflammation, and oncology.


    GSK said it would pay Adaptimmune up to 48 million pounds ($63 million) for the global license for the T-cell receptor therapy targeting the NY-ESO peptide, which is present across many cancer types.


    It is being used in studies to treat six types of cancer, including a rare form of soft tissue cancer, as well as in a combination study in multiple myeloma.


    GSK's head of oncology Axel Hoos said the company had seen compelling data for the NY-ESO investigational cell therapy in synovial sarcoma, which usually develops in cells around joints and tendons, and it will capitalize on its in-house cell and gene therapy capabilities to support its development.


    "We will continue to explore the potential for this novel cell therapy in multiple tumor types, and in combination with other cancer therapies," he said.


    Shares in Adaptimmune, which is based in Oxfordshire, southern England but listed in New York, were trading up 10 percent at $7.42 on Thursday.


    ($1 = 0.7648 pounds)




    (Reporting by Paul Sandle; editing by Alexander Smith)



    AdaptimmuneAxel Hooscancercancer therapydealEmma WalmsleyGSKHIVinfectious diseaseslicensemultiple myelomaoncologyrespiratorysoft tissue cancerT cell therapytumor
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok